|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||35.54 - 35.78|
|52 Week Range||28.74 - 35.90|
|Beta (3Y Monthly)||0.45|
|PE Ratio (TTM)||23.21|
|Forward Dividend & Yield||1.07 (3.05%)|
|1y Target Est||40.17|
Endeavor, formerly WME-IMG, the Hollywood and sports mega-agency run by Ari Emanuel, is going public on the NYSE. The agency filed its S-1 form with the SEC today and in it, Emanuel writes that the agency "has been a catalyst for culture-defining content for more than a century." It aims to raise $600 million.
Target is bringing back popular items from its past in celebration of its 20th anniversary of its first design collaboration. It features products from Lilly Pulitzer and Zac Posen and has clothes, bags, home decor and more. Yahoo Finance’s Dan Roberts, Brian Cheung and Julia La Roche discuss.
Billionaire Carl Icahn is moving his business to Florida, and bringing more than half of his staff with him. Icahn is reportedly making the switch to avoid New York's high taxes. Yahoo Finance’s Myles Udland, Jen Rogers and Julia La Roche discuss.
Biogen (BIIB) starts a DEVOTE study to investigate whether a higher dose of Spinraza can provide greater efficacy for treating patients with spinal muscular atrophy.
Roche and Transnet, the main freight logistics company in South Africa, came together in 1994 to establish Phelophepa, the world’s first comprehensive primary healthcare.
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Sept. 17.) 10X Genomics Inc (NASDAQ: TXG ) (listed ...
Roche has won the U.S. Food and Drug Administration's breakthrough therapy tag for its drug Gazyva in lupus nephritis, the Swiss drugmaker said on Wednesday, boosting its efforts to recycle the 2013-approved lymphoma medicine for new indications. There are no FDA-approved drugs for lupus nephritis, a life-threatening manifestation of the autoimmune disease lupus in which the kidneys grow inflamed. Roche has heralded Gazyva's potential in lupus in helping turn a medicine with 2018 sales of 390 million Swiss francs ($393 million) into a commercial success.
There are currently no U.S. FDA-approved medicines for lupus nephritis The designation is based on the results of the phase II NOBILITY study that showed Gazyva, in combination.
OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Gazyva® (obinutuzumab) for adults with lupus nephritis. This designation was granted based on data from the Phase II NOBILITY study in adult patients with proliferative lupus nephritis which showed Gazyva, in combination with standard of care (mycophenolate mofetil or mycophenolic acid and corticosteroids), demonstrated enhanced efficacy compared to placebo plus standard of care alone in achieving complete renal response at one year.
For many foreign companies that are publicly traded (or one day would like to be), cross-trading in the U.S. is a critical component of accessing U.S. investors. The U.S. is by far the largest market in the world. In terms of market cap and number of high-net-worth investors, the U.S. markets are nearly greater than the rest of the globe combined.
J&J's (JNJ) sBLA seeking approval for Tremfya for active psoriatic arthritis is based on data from the phase III DISCOVER 1 and 2 studies.
The Agriculture Transportation Coalition (AgTC) on Sept. 13 asked the FMC to extend the deadline for comments on the proposed interpretive rule from Oct. 17 to Oct. 31. "We believe this initiative to address unrelenting per diem fees, has the potential for being the most relevant and far-reaching initiative taken by the FMC in many years, in terms of its impact on the U.S. economy," said AgTC Executive Director Peter Friedmann in an interview. On Sept. 13, the FMC published on its website the notice of proposed interpretive rulemaking to address future demurrage and detention disputes brought before the commission by the container shipping industry.
Biogen (BIIB) and its Japanese partner, Eisai receive another setback as they discontinue two late-stage studies evaluating elenbecestat in patients with Alzheimer's disease.
OTCQX: RHHBY) has again been recognised as one of the most sustainable companies in the Pharmaceuticals index of the Dow Jones Sustainability Indices (DJSI). This is based on an in-depth analysis of economic, social and environmental performance.
Roche Diagnostics announced today that the US Food and Drug Administration (FDA) has cleared its cobas proⓇ integrated solutions, a new generation of Serum Work Area (clinical chemistry and immunochemistry) laboratory solution, designed to optimize lab operations. With the cobas pro integrated solutions, laboratories are now able to run tests faster on less equipment, automate manual tasks and deliver results more quickly to aid in treatment decisions.
Roche's (RHHBY) new fixed-dose combination of Perjeta and Herceptin meets the primary endpoint in the phase III study for treating patients with HER2-positive early breast cancer.
Glaxo's (GSK) Nucala gets FDA nod for use in kids. Pfizer (PFE), Allergan (AGN) & Roche (RHHBY) give regular pipeline/regulatory updates.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 11) Ardelyx Inc (NASDAQ: ARDX ) Avedro Inc (NASDAQ: AVDR ...
Roche's (RHHBY) immuno-oncology drug, Tecentriq, meets the primary goal in a late-stage study in NSCLC patients. Also, the company reports positive data on its NMOSD drug in a phase III study.
OTCQX: RHHBY), announced today longer-term data from the Phase III open-label extension studies of OPERA I, OPERA II and ORATORIO showed that patients who were treated with Ocrevus® (ocrelizumab) continuously for six years or more had reduced risk of disability progression in relapsing MS (RMS) and primary progressive MS (PPMS).
OTCQX: RHHBY) today announced longer-term data from the Phase III open-label extension studies of OPERA I, OPERA II and ORATORIO showed that patients who were treated with OCREVUS® (ocrelizumab) continuously for six years or more had reduced risk of disability progression in relapsing MS (RMS) and primary progressive MS (PPMS). “The effect of MS therapies on progression – not just relapses – is very important to help reduce the impact of the disease on the daily lives of people with MS and their families,” said Professor Gavin Giovannoni, Consultant Neurologist at Barts and the London School of Medicine and Dentistry. “The OCREVUS data at ECTRIMS highlight that the benefit of delaying, and possibly preventing, disability progression is greater when the treatment is used earlier in the disease course for both relapsing and primary progressive forms of MS.
The study showed a new investigational fixed-dose combination (FDC) of Perjeta® (pertuzumab) and Herceptin® (trastuzumab), administered by subcutaneous (SC) injection in combination with intravenous (IV) chemotherapy, demonstrated non-inferior levels of Perjeta in the blood (pharmacokinetics) compared to standard IV infusion of Perjeta plus Herceptin and chemotherapy in people with HER2-positive early breast cancer (eBC).